Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Terminated

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Placebo
Drug: QBW251

First Posted Date: 2020-02-13

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT04268823

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Phase 3

Terminated

Conditions: Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic

Interventions: Drug: Sabatolimab
Drug: Azacitidine
Drug: Placebo

First Posted Date: 2020-02-12

Last Posted Date: 2025-04-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 530

Registration Number: NCT04266301

Locations: 🇺🇸
University Of Miami, Miami, Florida, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 9 locations

Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration

Phase 3

Completed

Conditions: Neovascular Age-Related Macular Degeneration

Interventions: Drug: RTH258/Brolucizumab

First Posted Date: 2020-02-11

Last Posted Date: 2024-11-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 295

Registration Number: NCT04264819

Locations: 🇫🇷
Novartis Investigative Site, Vincennes, France

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Phase 1

Terminated

Conditions: In Escalation: All Patients With Solid Tumors and Lymphoma
In Expansion: Melanoma, Non-small Cell Lung Cancer

Interventions: Drug: NIZ985
Drug: Spartalizumab
Drug: Tislelizumab

First Posted Date: 2020-02-07

Last Posted Date: 2025-05-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT04261439

Locations: 🇺🇸
City of Hope National Medical, Duarte, California, United States
🇺🇸
Moores UCSD Cancer Center, La Jolla, California, United States
🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

Phase 3

Active, not recruiting

Conditions: Triple Negative Breast Neoplasms

Interventions: Drug: placebo
Drug: alpelisib
Drug: nab-paclitaxel

First Posted Date: 2020-02-05

Last Posted Date: 2025-05-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 137

Registration Number: NCT04251533

Locations: 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸
Hematology and Oncology Clinic, Baton Rouge, Louisiana, United States
🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States

and more 3 locations

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia
Non-Hodgkins Lymphoma

Interventions: Drug: JBH492

First Posted Date: 2020-01-27

Last Posted Date: 2024-10-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT04240704

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain

A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration

Phase 3

Completed

Conditions: Neovascular Age Related Macular Degeneration

Interventions: Drug: RTH258/Brolucizumab

First Posted Date: 2020-01-23

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 210

Registration Number: NCT04239027

Locations: 🇫🇷
Novartis Investigative Site, Toulouse Cedex 9, France

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Early Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: KAZ954
Drug: PDR001
Drug: NZV930
Drug: NIR178

First Posted Date: 2020-01-23

Last Posted Date: 2025-05-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 77

Registration Number: NCT04237649

Locations: 🇺🇸
University Of California LA, Los Angeles, California, United States
🇺🇸
Northwestern University Med School, Chicago, Illinois, United States
🇺🇸
Uni of TX MD Anderson Cancer Cntr, Houston, Texas, United States

and more 3 locations

A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)

Phase 3

Terminated

Conditions: Plaque Psoriasis
Non-alcoholic Fatty Liver Disease

Interventions: Biological: Control Arm - placebo
Biological: Investigational Arm - secukinumab

First Posted Date: 2020-01-23

Last Posted Date: 2024-02-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT04237116

Locations: 🇪🇸
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain

Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).

Phase 4

Recruiting

Conditions: Fascioliasis

Interventions: Drug: Egaten (Triclabendazole) 250 mg tablets

First Posted Date: 2020-01-18

Last Posted Date: 2025-06-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 300

Registration Number: NCT04230148

Locations: 🇻🇳
Novartis Investigative Site, Quy Nhon, Binh Dinh, Vietnam

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy